SureSeq

A Sysmex Group Company

Innovative NGS myeloid malignancy solutions

From sample to tertiary insights, bring clarity to your workflow

At OGT, we develop pioneering hybridization technology that fits seamlessly into your workflows. Leveraging rational, expert-driven development, our SureSeq myeloid range offers:

- **Enhanced detection of complex structural variants** – including those that are difficult for amplicon-based approaches
- **Better coverage uniformity** – even for hard-to-sequence GC rich regions of the genome
- **Clearer genetic profile of your sample** – with more unique fragments detected and reduced bias and error

SureSeq

Innovative NGS myeloid malignancy solutions

Simplify the way you work with NGS

Traditional research approaches for myeloid malignancies can consign your laboratory to complex and time-consuming multi-stage workflows.

Our SureSeq™ myeloid malignancy research solutions are underpinned by a universal workflow compatible across all disease areas and product applications, unlocking the simplicity and efficiency you need. With our NGS myeloid solutions you also reap the benefits of reliably detecting *FLT3*-ITDs so you can free yourself from additional testing.

Experience our fast, cost-effective myeloid NGS solutions and bring clarity to your workflow

1. Sample preparation

2. Genetic sequence

3. Variant detection
with Interpret software

4. Tertiary analysis
with QIAGEN QCI Interpret

Empowering you with the latest developments

Be assured you're capturing the most important targets with SureSeq panels designed in collaboration with leading cancer experts

Delivering exceptional uniformity

Confidently detect low-frequency SNVs and indels with our best-in-class design process, informed by our unique expertise, for exceptionally uniform coverage

Robust detection of challenging biomarkers

Analyze difficult biomarkers, including *CEBPA*, *NPM1*, *FLT3*-ITDs (including long ITDs in excess of 300 bp long) and *KMT2A*, with our hybridization-based approach and remove the need for supplementary approaches

Seamless customization at the touch of a button

Access a library of over 1000 pre-optimized targets or request novel targets, so you only sequence the biomarkers that matter most to you

SureSeq

Innovative NGS myeloid malignancy solutions

OGT has you covered no matter your research or myeloid malignancy focus. With our broad range of NGS products we cover the full myeloid disease spectrum, so we have the solution for you, every time.

With SureSeq, you can alleviate the burden of running multiple assays in a single panel. Our expertly designed NGS solutions provide outstanding coverage uniformity so you can robustly detect:

- Low frequency SNVs and indels
- *FLT3*-ITDS, including long ITDs in excess of 300 bp long
- *KMT2A*-PTDs of all sizes

Visit ogt.com/ngs-myeloid to find out more.

SureSeq Core MPN Panel

Robustly detect key variants associated with MPN, with the flexibility to include *BCR-ABL* fusion gene detection.

Product Code
780001-24, 780001-96

Reactions
24, 96

Panel Size
1 Kb

Number of Targets
3 key clinically relevant genes (±*BCR-ABL* fusion)

SureSeq Myeloid Plus Workflow

Accurately detect clinically relevant SNVs, indels and structural variants, even in challenging biomarkers, for a wide variety of myeloid malignancies.

Product Code
780002-24, 780002-96

Reactions
24, 96

Panel Size
132 Kb

Number of Targets
49 genes
(+4 sex chromosome genes)

SureSeq Pan-Myeloid Panel

Obtain a comprehensive picture of the genetic make-up of every myeloid sample you run.

Product Code
780003-24, 780003-96

Reactions
24, 96

Panel Size
221 Kb

Number of Targets
70 genes
(+4 sex chromosome genes)

SureSeq Myeloid Fusion Panel

Simultaneously detect all fusions of baited genes and enhance sample classification with novel/rare fusions.

Product Code
890001-24, 890001-96

Reactions
24, 96

Panel Size
61 Kb

Number of Targets
30+ fusions (+ partner gene-agnostic fusion detection for detection of novel fusion partners)

SureSeq Myeloid MRD Plus NGS Panel

Comprehensively interrogate a wide range of targets with highly sensitive detection as low as 0.01% VAF.

Product Code:
770045-48

Reactions:
48

Panel Size
12.4 Kb

Number of Targets
16 genes

SureSeq myPanel Custom AML Panel

Create your ideal panel with our sophisticated bait design strategies and sequence only what's relevant for your AML research.

Product Code
Upon request

Reactions
Upon request

Panel Size
Upon request

Number of Targets
Contact our team to begin designing your panel

SureSeq

Innovative NGS myeloid malignancy solutions

Unlock a complete sample to report NGS workflow

With SureSeq and QIAGEN Clinical Insight (QCI®) Interpret

OGT's partnership with **QIAGEN Digital Insights** allows our customers to package their SureSeq NGS panels and workflows with **QIAGEN QCI Interpret** tertiary analysis software. Now you can create an end-to-end NGS workflow with access to the world's largest knowledge base increasing confidence in variant classification.



Oxford Gene Technology

Panel Analysis: SureSeq Pan-Myeloid NGS Panel-OGT

Analysis results: Positive

2 Variants of strong clinical significance, Tier 1	Approved treatments	Other findings
DNMT3A: p.R882C , Pathogenic	5-azacytidine Decitabine	Trials: 1 Phase 2
IDH2: p.R172K , Pathogenic	Enasidenib	-
2 Variants of potential clinical significance, Tier 2	**Approved treatments**	**Other findings**
KRAS: p.G12A , Pathogenic	-	-
NRAS: p.G13R , Pathogenic	-	-

Interactions
None

Guidelines
Potentially relevant guidelines are reported in the "guidelines" section starting on page 2.

Approval

Electronically signed on: Jul 16, 2025 by Qiagen Example Report Signature, MD CLIA:12345

Report content

Result overview and approval	Page 1
Guidelines	Page 2
Treatment options	Page 2
Available clinical trials	Page 2
Variant details	Page 3
Report information	Page 10
Selected references	Page 11

Start your NGS journey with OGT today

Contact one of our myeloid NGS experts to discuss your project requirements.

Visit ogt.com/myeloid-ngs to find out more.

Ordering information

UK +44 (0) 1865 856800

US +1 914 467 5285

contact@ogt.com

ogt.com

A Sysmex Group Company

What binds us, makes us.

Oxford Gene Technology Inc., 520 White Plains Road, Suite 500, Tarrytown, NY 10591, USA